Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.

Autor: Hofling AA; Division of Imaging and Radiation Medicine, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland; august.hofling@fda.hhs.gov., Fotenos AF; Division of Imaging and Radiation Medicine, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland., Niu G; Division of Imaging and Radiation Medicine, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland., Fallah J; Division of Oncology 1, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland; and., Agrawal S; Division of Oncology 1, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland; and., Wang SJ; Division of Biometrics I, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland., Marzella L; Division of Imaging and Radiation Medicine, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
Jazyk: angličtina
Zdroj: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2022 Nov; Vol. 63 (11), pp. 1642-1643. Date of Electronic Publication: 2022 Jul 07.
DOI: 10.2967/jnumed.122.264299
Databáze: MEDLINE